Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer

• Tadashi Uwagawa ,

  Roles Writing – original draft

  * E-mail: uwatadashi@msn.com

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  https://orcid.org/0000-0002-7194-8427

  ⨯
• Taro Sakamoto,

  Roles Data curation

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯
• Takeshi Gocho,

  Roles Data curation

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯
• Hiroaki Shiba,

  Roles Data curation

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯
• Shinji Onda,

  Roles Data curation

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯
• Jungo Yasuda,

  Roles Data curation

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯
• Yoshihiro Shirai,

  Roles Data curation

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯
• Ryoga Hamura,

  Roles Data curation

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯
• Kenei Furukawa,

  Roles Data curation

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯
• Katsuhiko Yanaga,

  Roles Supervision

  Affiliation Department of Surgery, Fukuoka Sanno Hospital, Fukuoka, Japan

  https://orcid.org/0000-0001-8918-4720

  ⨯
• Toru Ikegami

  Roles Supervision

  Affiliation Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan

  ⨯